Navigation Links
Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease
Date:4/14/2014

SOUTH SAN FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a publication demonstrating that the company's C1s antibody prevents the destruction of human red blood cells exposed to plasma samples of patients with a type of autoimmune hemolytic anemia (AIHA). The article entitled "TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinin disease patient autoantibodies" was published on-line in the journal Blood earlier this month. TNT003 is the murine analog of True North's lead humanized monoclonal antibody drug candidate, TNT009, for which the company plans to initiate the first clinical program in 2015.

In ex vivo studies using plasma samples from patients with a type of AIHA known as cold agglutinin disease (CAD), True North demonstrated that red blood cells exposed to patient samples contained high levels of Complement proteins deposited on the cell surface. True North showed that by inhibiting Complement deposition on the red blood cell membrane, TNT003 prevented the red blood cells from being engulfed by macrophages, immune cells responsible for clearing Complement-coated cells and debris from the blood. TNT003 also prevented direct red blood cell lysis driven by a CAD sample that contained unusually high levels of autoantibodies, suggesting that a Complement inhibitor like TNT003 could be efficacious in severe cases of CAD.

"By selectively shutting down the Classical Complement pathway with an antibody, the main drivers of anemia in CAD have been reduced in this preclinical study. Using TNT003 and a large number of 40 patient samples, we were able to deepen the field's understanding of the Complement system's role in this rare disease. The study strengthens the hypothesis that such an approach could be beneficial in this rare patient population," stated Sandip Panicker, PhD, C1s Program Lead and senior author on the journal article in Blood.

TNT003 inhibits C1s, a member of the Complement family of plasma proteins, which, upon activation, trigger a powerful enzymatic cascade that destroys and removes pathogens from the circulation. However, aberrant Complement system activation has been described in numerous autoimmune settings in which antibodies that attack self, known as autoantibodies, play a role in disease pathogenesis. Like other forms of AIHA, CAD is a disorder in which anti-red blood cell antibodies bind to and lead to the destruction of patient red blood cells through Complement system activation.

Dr. Panicker further stated, "As Complement system activity is the only known driver of red blood cell destruction in patients with CAD, the results in the study published in Blood provide compelling evidence for the development of TNT009, the company's lead humanized monoclonal antibody, for the treatment of CAD and potentially other forms of AIHA, for which no approved therapies exist."


'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
845-635-9828
The Yates Network
Source:Eurekalert

Related medicine news :

1. Does the bodys immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?
2. Human stem cells predict efficacy of Alzheimer drugs
3. Osteoporosis drugs compared for side effects, efficacy in Loyola study
4. Despite missing primary efficacy endpoint, ATOMIC-AHF identifies positive trends
5. CHERISH trial demonstrates efficacy of tocilizumab in juvenile idiopathic arthritis
6. Long-term apremilast demonstrates continued efficacy in patients with psoriatic arthritis
7. Registry confirms TAVI efficacy and safety in Asian patients
8. Minocycline Enhances the Efficacy of Perispinal Enbrel in Traumatic Brain Injury Treatment as well as Stroke Treatment and Alzheimer’s Treatment
9. CycleBeads Natural Birth Control Method Ranks High in Perfect Use and Typical Use Efficacy According to Most Recent Review of Global Family Planning Reports
10. Study shows long-term efficacy of minimally invasive therapy for patients with Barretts esophagus
11. Muscular Development Store Comments on Efficacy of Protein Blends
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Our ... to overwork even the sharpest brain. , Power On, a mental performance enhancer ... over clocking the brain. Each capsule contains Cognizin® Citicoline, a branded form of ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... The ... to the thousands of individuals who have recently fallen victim to America’s opioid epidemic. ... in Orange County, California, where they are free from the shame, stigma, and ...
(Date:2/22/2017)... ... February 22, 2017 , ... South Bend’s Lunkerville, the award-winning TV series that ... On The Water (HOW), a non-profit organization dedicated to helping military veterans relax, rehabilitate, ... ‘Mike D’ traveling to Lake Denmark, New Jersey, to fish with war veteran Justin ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... chronic conditions reported skipping doses or not filling a prescription because they could ... rates of cost-related problems getting medications were 30-60%*. At the same ...
(Date:2/22/2017)... ... ... Sideline Products participated in the World Horse Expo held in Timonium, MD ... production crew. Tom Seay’s program “Best of America by Horseback” is broadcasted on ... be featured on April 6, 2017. After the broadcast, the clip will be posted ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... The Senior Care Pharmacy Coalition (SCPC) today ... of Representatives that will curtail the ability of drug ... extracting retroactive direct and indirect remuneration (DIR) fees in ... the Medicare program. S. 413, introduced by ... Jon Tester (D-MT), and House companion bill, H.R. ...
(Date:2/22/2017)... 2017 Henry Schein Medical today announced ... with Rijuven, which develops innovative digital medical devices, ... practitioners. CardioSleeve is a stethoscope ... sound signals, transmits real-time data to any smartphone ... to help physicians provide diagnostic interpretation of a ...
(Date:2/22/2017)... 2017  Allergan plc (NYSE: AGN), a leading ... Gold sponsor of the Alzheimer,s Foundation of America,s ... tour commemorates AFA,s15 years of educating individuals about ... The tour will include AFA,s free Concepts in ... of the AFA Quilt to Remember. ...
Breaking Medicine Technology: